As a BTKi, in addition to inhibiting BTK, ibrutinib can inhibit several other intracellular molecules important for platelet signalling, including tyrosine kinase expressed in hepatocellular carcinoma (Tec) [33]. Here, BTK is linked to hepatocellular carcinoma.